No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CERT Certara
- 14.890
- +0.250+1.71%
Close Jun 14 16:00 ET
- 15.190
- +0.300+2.01%
Post 19:49 ET
2.39BMarket Cap-38179P/E (TTM)
14.940High14.381Low717.44KVolume14.500Open14.640Pre Close10.62MTurnover0.65%Turnover RatioLossP/E (Static)160.84MShares19.87052wk High2.27P/B1.64BFloat Cap11.81052wk Low--Dividend TTM109.90MShs Float45.480Historical High--Div YieldTTM3.82%Amplitude10.600Historical Low14.798Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Stocks With the Highest and Lowest Liquidity - Goldman Sachs
Certara to Participate in the Jefferies Global Healthcare Conference
RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.
Investor Optimism Abounds Certara, Inc. (NASDAQ:CERT) But Growth Is Lacking
Certara, Inc.'s (NASDAQ:CERT) price-to-sales (or "P/S") ratio of 7.5x may look like a poor investment opportunity when you consider close to half the companies in the Healthcare Services industry in t
Express News | Certara Appoints New Chief Human Resources Officer & General Counsel
Drug Discovery Informatics Market Worth $8.17 Billion by 2031: Global Industry Analysis Featuring Profiles of Certara, Infosys, Collaborative Drug Discovery, Jubliant Biosys, Curia Global
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Comments
The fact that Certara is now generating some pre-tax profits from its prior investments is very encouraging. The promising trends warrant this stock for further investigation despite its current low returns compared to the industry average.
Returns At Certara (NASDAQ:CERT) Are On The Way Up 1
Acquisition of Applied BioMath by Certara could enhance QSP biosimulation adoption in life sciences, revolutionizing drug invention. This may impact the drug discovery process, improving decisions and reducing late stage attrition rates.
Amid less promising revenue projections, Certara's surprisingly high P/S ratio indicates investor hopes for a business rebound. However, analysts remain skeptical, suggesting shareholders may face disappointment if the P/S ratio rebalances with growth outlook.
Pre-Market Stock Movers
Gapping up
$Fabrinet(FN.US$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin(APP.US$
...
Gapping up
$Fabrinet(FN.US$
(Fabrinet surged 21% after its fiscal fourth-quarter results late Monday topped analysts' estimates. The advanced manufacturing services company posted non-GAAP earnings of $1.86 per share, greater than the $1.80 earnings per share expected by analysts polled by FactSet. Revenue came in at $655.9 million, greater than the $641.4 million consensus estimate.)
$Applovin(APP.US$
...
22
1
$Bridger Aerospace(BAER.US$ $Couchbase(BASE.US$ $Certara(CERT.US$ $Coherus BioSciences(CHRS.US$ $Torrid(CURV.US$ $Dollar General(DG.US$ $EPAM Systems(EPAM.US$ $First Horizon National(FHN.US$ $Forza X1(FRZA.US$ $GameStop(GME.US$ $MGO Global(MGOL.US$ $Altria(MO.US$ $Mondee Holdings(MOND.US$ $Rent the Runway(RENT.US$ $Smartsheet(SMAR.US$ $Semtech(SMTC.US$
1
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg